HPLC vs Mass Spectrometry — Peptide Analysis Methods Compared | Regena

Reverse-phase HPLC (RP-HPLC) separates a peptide sample by passing it through a non-polar stationary phase under a gradient of increasingly organic mobile phase. Different molecules elute at different times based on their hydrophobicity, and the detector (typically UV absorbance at 214–220 nm) records the area under each peak. The main peak is the target peptide; smaller peaks are related impurities.

The output is a chromatogram with peaks expressed as a percentage of total integrated peak area. Main-peak purity is the headline number on every credible peptide COA, and the related-impurities profile is the supporting detail.

HPLC measures separation, not identity. Two molecules that elute at the same retention time are quantified as a single peak, even if they are chemically different. A peptide of the wrong sequence but the right hydrophobicity can show as a single clean main peak on HPLC alone — which is why HPLC on its own is not sufficient identity confirmation.

HPLC is also blind to the molecular weight of the eluted peak. A truncated sequence missing a single amino acid can elute close enough to the target peptide to integrate into the same main peak; only mass spectrometry will catch that.

Electrospray mass spectrometry (ESI-MS) ionises the sample and measures the mass-to-charge ratio of the resulting ions. For a peptide, the output is the molecular weight of the molecule — which can then be compared to the theoretical molecular weight calculated from the sequence.

A match within instrument tolerance (typically a fraction of one Dalton for a peptide in the 1–5 kDa range) confirms that the analysed peak is in fact the compound named on the label. A mismatch means the batch is not what the label says it is — the single most serious COA flag.

Mass spectrometry confirms identity, not purity. A clean MS spectrum at the correct molecular weight does not mean the rest of the sample is also at the correct molecular weight — it means the detected ions, in the part of the spectrum the instrument was looking at, match.

Mass spectrometry is also blind to stereochemistry. Two peptides with the same composition but different chirality at one or more residues will have the same molecular weight; only orthogonal methods (circular dichroism, NMR, chiral HPLC) will distinguish them. For most research-grade peptide work this is not a practical concern, but it is worth knowing.

HPLC tells you how clean the batch is. Mass spectrometry tells you whether the clean fraction is what the label says it is. Together they answer the two questions a research-peptide buyer most needs answered: is this the right molecule, and is it pure enough for the protocol?

A COA that includes only HPLC could be reporting a clean batch of the wrong compound. A COA that includes only mass spectrometry could be confirming the right compound in an impure batch. Regena's release specification requires both — HPLC ≥99.0% main peak AND mass-spectrometry molecular weight matching theoretical within tolerance — for every batch.

The HPLC panel shows the chromatogram (retention time on the x-axis, absorbance on the y-axis), the integration table listing each peak with its retention time and percentage area, and the main-peak purity headline number. Look for: a single dominant peak with retention time matching the published method for the compound, related impurities reported as a percentage of total area, and a main-peak purity at or above the release specification.

Methodologically, a 30-minute gradient on a C18 column with UV detection at 214 nm is the standard reverse-phase setup for peptide analysis. Janoshik Analytical publishes its method parameters and they are consistent across Regena's batch history.

The mass-spectrometry panel shows the ESI spectrum (mass-to-charge on the x-axis, intensity on the y-axis), the deconvoluted molecular weight, the theoretical molecular weight calculated from the sequence, and the difference between the two. For a peptide in the 1–5 kDa range, an agreement within a fraction of one Dalton is the expected tolerance.

For peptides with modifications (e.g. tesamorelin's trans-3-hexenoyl group, fatty-acid acylated analogues), the panel should explicitly confirm the modification — the molecular weight should match the modified sequence, not the base sequence. A panel that reports only the base-sequence weight on a modified peptide is an incomplete identity confirmation.

For most research-peptide batches, HPLC and ESI-MS are sufficient. For complex modifications, isomeric analogues, or batches destined for a particularly sensitive protocol, Regena adds orthogonal methods on request: tandem MS/MS for sequence confirmation, Karl Fischer titration for water content, circular dichroism for secondary-structure confirmation, or chiral HPLC for stereochemistry.

Add-on analytical work is arranged through the consultations team and the extended COA is delivered alongside the standard Janoshik report.